hand exercises for rheumatoid arthritis pdf

πŸ”₯+ hand exercises for rheumatoid arthritis pdf 07 Jul 2020 A rheumatoid arthritis diagnosis can be shocking to young adults. Life plans, including a career and family, may need to change. Learn about ...

hand exercises for rheumatoid arthritis pdf The goals of treatment are to relieve pain, reduce swelling, increase joint mobility and strength, and prevent joint damage and complications.

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Dtsch Arztebl Int. 2017 Mar; 114(13): 215–222.
Published online 2017 Mar 31. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for doi:Β 10.3238/arztebl.2017.0215
PMCID: PMC5624445
PMID: 28434436
Review Article
Bettina Engel, Dr. med.,1,* Johannes Just, Dr. med.,1 Markus Bleckwenn, Dr. med.,1 and Klaus Weckbecker, Prof. Dr. med.1

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Bettina Engel

1Institute of General Practice and Family Medicine, University Hospital Bonn

Find articles by Bettina Engel

Johannes Just

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for 1Institute of General Practice and Family Medicine, University Hospital Bonn

Find articles by Johannes Just

Markus Bleckwenn

1Institute of General Practice and Family Medicine, University Hospital Bonn

Find articles by Markus Bleckwenn

Klaus Weckbecker

1Institute of General Practice and Family Medicine, University Hospital Bonn

Find articles by Klaus Weckbecker
1Institute of General Practice and Family Medicine, University Hospital Bonn
*Institut für Hausarztmedizin Universitätsklinikum Bonn/Medizinische Fakultät 53127 Bonn, Germany [email protected]
Received 2016 Jul 21; Accepted 2016 Dec 29.
See letter ""/pmc/articles/PMC5569560/"" in volume 114 onΒ pageΒ 506.
See letter ""/pmc/articles/PMC5569561/"" in volume 114 onΒ pageΒ 506.
See letter ""/pmc/articles/PMC5569562/"" in volume 114 onΒ pageΒ 506.
This article has been cited by other articles in PMC.

Abstract

Background

1–2% of adults in Germany suffer from gout. Gout is one of the few rheumatological diseases that can be cured. It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia. Painful redness and swelling of the affected joints are typical findings. Multiple pertinent guidelines and treatment recommendations have been published, but there is reason to believe that patients with gout are not always treated accordingly.

Methods

This review is based on relevant publications from the years 2000–2016 that were retrieved by a selective search in the Cochrane and PubMed databases.

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Results

In a person with normal renal function, asymptomatic hyperuricemia is not an indication for treatment to lower the serum uric acid level. The drugs of first choice for acute gouty arthritis are nonsteroidal anti-inflammatory drugs (NSAID), corticosteroids, and colchicine. Treatment with xanthine oxidase inhibitors (XOI) or uricosuric drugs is indicated for patients with a recurrent or severe course; the target uric acid value is <6 mg/dL. Long-term treatment should be initiated only after resolution of the acute attack. For patients with refractory gout, lesinurad (approved in February 2016) in combination with XOI is a new treatment option that can be considered. Comprehensive patient education and counseling is an important component of the treatment of patients with gout. Regular laboratory follow-up is necessary as well.

Conclusion

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for The prevalence of gout is rising around the world. Patients with gout could benefit greatly from consistent implementation of the existing treatment guidelines and recommendations. In the future, controlled trials should be conducted to determine the best time to start treatment and the optimal target level for the serum uric acid concentration in terms of a risk/benefit analysis.

Approximately 1 to 2% of adults in Germany suffer from gout and around 20% from hyperuricemia. This makes gout the most widespread form of arthritis nationwide (1). It is one of the few rheumatic diseases that can be cured. Gout is caused by the deposition of uric acid crystals in joints or in tissues around joints as a result of hyperuricemia. Typically, painful swelling and reddening occur in the affected joint. An increase in the prevalence and incidence of gout has been observed worldwide (e1). There is no data on Germany specifically. However, because current incidence levels are similar to the incidence found in Annemans’ study (1), it can be inferred that the situation in Germany is the same. Attention has shifted back to gout for both health-related and economic reasons (1, 2, e1). In the past, multiple guidelines and treatment recommendations were published in order to improve care for gout patients. However, care currently fails to comply with these guidelines in a number of ways. These include overuse of allopurinol for asymptomatic patients with hyperuricemia and a failure to monitor uric acid-lowering drug therapy. Multiple studies have shown this discrepancy between treatment recommendations and clinical practice (3, 4, e1e3).

Methods

The authors performed a selective search of the literature for the years 2000 to 2016 in the Cochrane Database and in PubMed. In PubMed the following search terms were used: “gout” OR “hyperuricemia”; filters activated: “meta-analysis,” “systematic reviews,” “randomized controlled trial,” “guideline,” “clinical trial,” “abstract,” “publication date from 2000/01/01,” “humans,” “English,” “German.” The initial search yielded 628 hits. Following the analysis of titles and abstracts, 159 sources remained; these were used as the basis for a qualitative synthesis. Some older, basic publications were added individually. A detailed description of the procedure, which complied with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) Statement, is available from the authors.

Results

Our search yielded little literature of high quality in terms of level of evidence and study design. This article states the grade of each recommendation according to the most recent guidelines (5, 6) in parentheses.

Definitions

Gout the 1 last update 2020/07/07 is divided into 4 stages (e4):Gout is divided into 4 stages (e4):

  • Asymptomatic deposits in tissues

  • Acute gout: This is defined as rapidly-developing inflammation, usually of only one joint, with painful overheating and swelling. Uric acid crystals trigger the inflammation reaction in joints or tissues around joints.

  • Intercritical periods: These are clinically inactive disease phases between 2 flares. During these periods, gout patients also have hyperuricemia, which can lead to increased deposition of urate crystals in tissues. Intercritical periods become shorter as the disease progresses.

  • Chronic gout: This is characterized by long-term joint inflammation, which leads to joint pain at rest and/or on movement.

Prevalence

According to the European League Against Rheumatism (EULAR), the prevalence of symptomatic gout among the adult Western population is 1 to 2% (7), rising to 7% in those aged over 65 years (1). Publications to date do not give prevalence figures for individual stages of gout.According to the European League Against Rheumatism (EULAR), the prevalence of symptomatic gout among the adult Western population is 1 to 2% (7), rising to 7% in those aged over 65 years (1). Publications to date do not give prevalence figures for individual stages of gout.

Etiology

Gout can be caused by overproduction of uric acid (10% of cases) or lowered renal uric acid excretion (90%) (e5). Rarer causes of gout are genetic purine metabolism disorders such as the Lesch–Nyhan syndrome (e6).

Uric acid is the end product of purine metabolism in humans. The solubility product of uric acid at 37 °C is 6.8 mg/dL (8). Hyperuricemia can favor the precipitation of urate crystals in tissues, leading to gout. Incidence of gout rises with uric acid level (9) (table 1). Uric acid crystals precipitate faster at lower temperatures, so toes, fingers, hands, feet, elbows, and ears are the principal sites of gout flares and deposition of uric acid crystals in soft tissues (gout tophi). Uric acid crystals may also be deposited in the urinary tract (urolithiasis).

Table 1

Gout incidence by serum uric acid level*
Serum uric acid (mg/dL)Incidence (%/year)
<70.1
7.0 to 8.90.5
≥ 94.9

*according to Campion et al. (9)

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for The uric acid crystals that have precipitated lead to inflammasome activation in monocytes and the subsequent release of various inflammatory mediators such as interleukin-1 (10). If left untreated, an acute gout flare lasts between 3 days and 2 weeks. A patient’s first gout flare is monoarthritis in up to 90% of cases, most commonly inflammation of the joint at the base of the big toe (podagra) (11). Polyarthritis is more common in older patients (4).

Diagnosis

In primary care practice, a gout flare is diagnosed on the basis of examination (typical pattern of involvement) and medial history (after ruling out red flags: trauma, condition following intra-articular injection, surgery, fever, poor general health) (e7). In 2015 the US and European rheumatology societies (the American College of Rheumatology [ACR] and EULAR respectively) developed a clinical diagnosis score (12) (table 2). These diagnosis criteria state that evidence of uric acid crystals on joint puncture is sufficient to confirm a diagnosis of gout. Due to risk/benefit considerations, these authors advise against diagnostic puncture where clinical findings unambiguously indicate a gout flare (C).

Table 2

Diagnosis criteria for gout*
CriterionCharacteristicsPoints
Pattern of involvementAnkle/foot
MTP-1
1
2
Symptoms:
– Erythema of joint
– Affected joint very sensitive to touch
– Movement very limited
1/3 symptoms
2/3 symptoms
All 3 symptoms
1
2
3
Criteria for typical episode:
– Pain develops within 24 hours
– Resolves after ≤14 days
– Complaint-free intervals
1 typical episode
Multiple typical episodes
1
2
Evidence of tophusPresent4
Laboratory tests:
– Serum uric acid (preferably without treatment, 4 weeks before/after an episode or highest value during episode)
– Joint fluid analysis following puncture (if performed)
<4 mg/dl
6 to 8 mg/dL
8 to <10 mg/dl
≥10 mg/dL
No urate crystals
–4
2
3
4
–2
Imaging:
– Urate deposits on ultrasound or DECT
– Erosions characteristic of gout on conventional X-ray
Present
Present
4
4

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for According to Neogi et al. (12)

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for *If swelling score is 8 or more out of a maximum of 23 points, arthritis can be classified as gout with a sensitivity of 92% and a specificity of 89%. Evidence of uric acid crystals on puncture is a sufficient criterion.

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for DECT: Dual-energy computed tomography; MTP-1: Metatarsophalangeal the 1 last update 2020/07/07 joint IDECT: Dual-energy computed tomography; MTP-1: Metatarsophalangeal joint I

Laboratory and X-ray analysis

One-third of patients with an acute gout flare have normal uric acid levels (e8). A normal serum uric acid level in cases of acute arthritis does not rule out gouty arthritis. A high uric acid level increases the probability of gouty arthritis but does not confirm the diagnosis (12) (C). In an acute gout flare, uric acid precipitates and, as uric acid crystals, causes the patient’s complaints; this may lead to a reduction in the measurable blood uric acid level. Uric acid level measurement a few weeks after a flare in order to monitor disease progression is recommended (13) (B).

Laboratory tests may be necessary for further clarification in cases of atypical progression or for differential diagnosis. The following diseases must be considered in differential diagnosis of acute gout:

  • Septic arthritis

  • for 1 last update 2020/07/07 TraumaTrauma

  • hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Active arthritis

  • Pseudogout

  • Rheumatoid arthritis

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Annual laboratory tests, particularly of retention levels and uric acid level, should be performed to monitor the progression of chronic gout (14) (B).

To date, conventional imaging has not played a major role in primary diagnosis, as gout does not cause radiologically visible bone changes until it has progressed to a late stage (e9). Earlier detection of tophi in soft tissues may be used to monitor treatment in the future. Ultrasound examination can be used as a noninvasive option. Sonography shows synovialitis with markedly increased vascularization and a double contour sign. (e10, 15). Dual-energy CT (DECT) can reveal small deposits of uric acid crystals but should only be considered if findings for differential diagnoses are unclear, as it involves radiation exposure, is expensive, and has low overall sensitivity (15) (C).

Treatment

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Gout treatment rests on 2 pillars: nonpharmacological and pharmacological therapy. How much of each should be used depends on the individual patient’s needs. Stage (acute gout, intercritical phase, or chronic gout), individual factors (number of flares, radiological findings), and general risk factors play a the 1 last update 2020/07/07 crucial role in this.Gout treatment rests on 2 pillars: nonpharmacological and pharmacological therapy. How much of each should be used depends on the individual patient’s needs. Stage (acute gout, intercritical phase, or chronic gout), individual factors (number of flares, radiological findings), and general risk factors play a crucial role in this.

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Nonpharmacological therapy

This includes patient education, dietary recommendations, and resting the joint.

Patient education (C): One approach to gout treatment is patient education. Hyperuricemia is more common with current lifestyle trends (increasing lack of exercise, excess weight). A cohort study conducted in England showed that detailed education led to successful gout management by patients (e11).

Dietary recommendations: Diet affects uric acid levels. Changes to diet and lifestyle can reduce uric acid levels by up to 18% (16). Several studies have shown that less than 50% of gout patients surveyed were informed of the association between particular foods and gout (e12).

Many authors recommend the same diet as for cardiovascular event prevention (www.degam.de/patienteninformationen.html—in German). A large cohort study has shown that weight loss and subsequently improved metabolic status can also reduce the incidence of gout flares (e13) (B). Dietary recommendations (box) are based on pathophysiological considerations and are compatible with other healthy dietary recommendations. No randomized controlled trials have yet investigated whether the recommendations have a positive effect on patients’ gout progression (17).

BOX

hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Dietary recommendations for gout (16, e13)

  • Overweight patients should aim for a normal weight but should not crash-diet or follow protein-rich diets such as the Atkins diet.

  • Reduced-fat foods and vegetarian sources of protein should be integrated into the diet.

  • Protein-rich foods such as meat, offal, crustaceans, and yeast should be avoided.

  • Patients known to suffer from gout and kidney stones should be instructed to consume sufficient fluids (>2 L /day).

  • Consumption of alcohol, particularly beer and spirits, should be reduced. Patients should be encouraged to refrain from consuming alcohol on at least 3 days per week.

  • Sugar-sweetened beverages should be avoided. One study showed that consumption of soft drinks and drinks containing fructose entailed an increased risk of a gout flare (e14). Fructose inhibits uric acid excretion by the kidneys.

Resting the joint: A systematic review showed that correct rest for the joint can also contribute to the treatment of an acute gout flare. The affected joint should be raised and cooled (18) (C).

Pharmacological therapy for acute gout

Pharmacological therapy for acute gout aims to achieve an absence of pain and resolution of joint inflammation as rapidly as possible. Without pharmacological treatment, a gout flare lasts between 3 days and 2 weeks. In general, anti-inflammatory therapy should be begun immediately, preferably within 12 to 24 hours of onset of an acute gout flare (B). First-line treatment options are nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and colchicine (5) (A). Treatment usually relieves symptoms after 24 hours (19). The decision which of the 3 substance groups to use depends on the patient’s comorbidities and the physician’s experience. Table 3 provides an overview of treatment options.

Table 3

Treatment options for acute gout
Substance/groupProposed therapyAdverse drug effectsMajor
contraindications
Recommendation gradeComments
Nonsteroidal antiinflammatory drugs (NSAIDs) POMaximum dose; 5 to 10 days or until symptoms resolveRenal dysfunctionRenal failure(A) Cochrane review: NSAID treatment option for acute gout flare (19)Early start of treatment more important than choice of NSAID
Corticosteroids PO30 to 35 mg prednisolone PO for 5 daysOverproduction of stomach acid, Cushing’s syndrome, metabolism disorder, hypertension/hypotension– Infection in particular
– Poorly managed diabetes mellitus or arterial hypertension
– Ulcerating wound(s)
(A) RCT: Corticosteroids have no disadvantages versus NSAIDs (20)
Colchicine POLow-dose therapy:
2 × 0.5 mg initially, then single administration 0.5 mg after 1 hour
Gastrointestinal effects in particularReduced creatinine clearance or liver failure; concomitant administration of CYP3A4 inhibitors, e.g. statins (5, 21)(A) RCT: Low-dose therapy has the same clinical effect as higher dose and fewer adverse effects (22)If gout flare was no longer than 24 hours ago
Cortisone IA or IMOverproduction of stomach acid, Cushing’s syndrome, metabolism disorder, hypertension/hypotension(B) Cochrane review: no evidence to date of clinically significant superiority over oral corticosteroid therapy (23)IM or IA corticosteroid injection possible in exceptional cases
Interleukin-1
antagonistsCanakinumab SC
Single administration (150 mg SC), repeat administration after no less than 12 weeks (24)Infections (e.g. urinary tract infections, airway infections); local skin reactions at site of injectionIf active infections present(B) Cochrane review: more effective than 40 mg triamcinolone IM (24)If all 3 standard treatment options contrain‧dicated/not tolerated

IA: Intra-articular; IM: Intramuscular; NSAID: Nonsteroidal anti-inflammatory drug; PO: Per os; SC: subcutaneous; RCT: Randomized controlled trial

In addition, it is recommended that treatment with drugs that induce hyperuricemia, particularly diuretics and low-dose acetylsalicylic acid, should not be begun in patients with acute gout, and that the dose of established therapy should not be increased (5, 16) (B).

Gout patients occasionally suffer from comorbidities that are incompatible with NSAID, colchicine, or cortisone treatment. Recent studies have shown that interleukin-1 is an important mediator of inflammation in acute gout. According to a Cochrane review (24), interleukin-1 antagonists can be considered as an alternative option if all 3 standard treatment options are contraindicated or not tolerated (B).

Uric acid-lowering drugs used to treat chronic gout are contraindicated for the treatment of acute gout flares, as they can also cause acute gout flares (25) (C). Long-established uric acid-lowering therapy should continue to be administered during an acute gout flare.

Treatment of asymptomatic hyperuricemia

Studies published to date indicate that treatment for asymptomatic hyperuricemia in patients with healthy kidneys cannot be recommended (26) (C). Two meta-analyses indicate an increase in cardiovascular risk in particular for hyperuricemia patients (e15, 21). However, there are no available studies that yield an unambiguous conclusion. In in vitro studies, uric acid has shown an antioxidant and therefore protective effect (e16). Further studies on this are required.

Chronic gout treatment

Chronic gout treatment should aim to prevent gout progression and further gout flares, to eliminate any urate deposits, and to reverse tophus formation. International guidelines recommend that uric acid levels be adjusted to well below the solubility limit of 6.8 mg/dL in order to prevent deposits (14, 16, e11). There are currently no available studies that have investigated the optimum target uric acid levels. The German College of General Practitioners and Family Physicians (DEGAM, Deutsche Gesellschaft für Allgemeinmedizin) recommends that uric acid levels should be maintained below 6.5 mg (27). The EULAR advises uric acid levels of less than 6 mg/dL, and even as low as <5 mg/dL in patients with severe gout (B). Lifelong therapy is recommended. A prospective cohort study has shown that withdrawal can be attempted after uric acid levels have successfully been maintained at a low level for more than 5 years (28) (B).

Long-term therapy should begin no sooner than 2 weeks for 1 last update 2020/07/07 after the beginning of an acute gout flare (B).Long-term therapy should begin no sooner than 2 weeks after the beginning of an acute gout flare (B).

Long-term therapy is recommended for patients with the following symptoms (16, 27) (B):

  • More than 2 gout flares per year

  • Urolithiasis and gout

  • Known overproduction of uric acid, e.g. during chemotherapy

  • Pre-existing tophi

According to EULAR recommendations, the option of beginning treatment early should be discussed with patients in order to reduce crystallization if gout does continue to progress (6). However, there is no clear evidence supporting this. Because allopurinol also has side effects and can lead to increased gout flares, particularly after the beginning of treatment, these authors recommend that patients should first try to reduce their uric acid levels through lifestyle changes.

Increased gout flares may occur in the first weeks to months after the beginning of uric acid-lowering treatment. When serum uric acid levels fall, uric acid deposits are mobilized from the tissues (e8, 29, 30). There are no randomized controlled trials on gout flare prophylaxis. Current knowledge has been obtained from febuxostat authorization studies and other sources (5). More gout flares have been described after the beginning of febuxostat treatment than of allopurinol treatment; however, there are no significant differences after longer-term administration. It is recommended that uric acid-lowering treatment be begun with a gradual dose increase (6) (C). Low-dose colchicine (0.5 mg/day) or a low-dose NSAID is recommended for 6 months to prevent flares (31, 32) (B).

International guidelines describe xanthine oxidase inhibitors as first-line treatment and uricosuric agents as second-line treatment. The leading xanthine oxidase inhibitor and uricosuric agent are allopurinol and probenecid respectively. Possible treatment options are listed in Table 4. A higher proportion of patients achieve the target uric acid level of 6 mg/dL with febuxostat—which is also a xanthine oxidase inhibitor—than with allopurinol (48% versus 22% [32]). Febuxostat is therefore a possible option for treatment-refractory hyperuricemia. Should this escalation be insufficient, combination therapy with a xanthine oxidase inhibitor and lesinurad, a selective inhibitor of the URAT1 transporter, is possible. In general, regular laboratory testing should be performed to monitor treatment success, and treatment should be adjusted if necessary (C). Urate oxidase should also be mentioned as a treatment option for treatment-refractory patients. However, this drug was taken off the market in mid-2016.

Table 4

Treatment options for chronic gout
Substance/groupProposed therapyAdverse drug effectsMajor contraindicationsRecommendation gradeComments
Xanthine oxidase inhibitor: allopurinolInitially 50 to 100 mg/day; increase to max. 800 mg/dayDiarrhea, nausea, vomiting, increased liver enzymes, skin reactions (2%), hypersensitivity syndrome (0.1%) (e17)Known hypersensitivity to allopurinol(A) Cochrane review: target serum uric acid levels achieved more frequently with allopurinol than with placebo (33)Adjust dose in cases of known renal failure (etable) Monitor liver and kidney enzyme levels
Xanthine oxidase inhibitor: febuxostatInitially 80 mg/day, increase to 120 mg/day if necessaryLiver dysfunction, diarrhea, nausea, headache, skin rashIschemic heart disease <12 months or decompensated heart failure (32, 34, e19)(A) Cochrane review: lowers uric acid levels more effectively than allopurinol (34)If allopurinol not toler‧ated, in cases of renal failure, or if target uric acid level not achieved despite increased allopurinol dose (A)
Uricosuric agent: probenecidProbenecid can be combined with allopurinol if allopurinol alone is insufficiently effective (5)Irritation of gastrointestinal tract, skin reactions, anorexiaUrolithiasis, advanced renal failure (creatinine clearance <50 ml/min), or increased uric acid production (e.g. during chemotherapy) (5, 14)(B) There are no placebo-controlled trials of uricosuric agents. RCT (35): probenecid less effective than allopurinol Take with sufficient fluids to prevent kidney stone formation
Selective inhibitor of URAT1 transporter: lesinuradAuthorized in combination with xanthine oxidase inhibitor for treatment-refractory cases since February 2016 (36)Headache, influenza-like symptoms increased creatinine levels, gastroesophageal refluxSevere renal failure, tumor lysis syndrome, Lesch–Nyhan syndrome(B) RCT: lowers uric acid levels more effectively in combination with allopurinol (37)Further studies required on cardiovascular safety according to the European Medicines Agency (EMA) (e20). Therefore not currently recommended by these authors for patients with cardiovascular events <12 months (c).
Uricosuric agent: benzbromaroneNot recommended by these authors due to liver toxicity (38) (C)
Uricase: pegloticaseTaken off the market in July 2016 (e21)Uric acid levels reduced due to breakdown of uric acid into allantoin, which is eliminated in the urine. Adverse drug effects: infusion issues, anaphylaxis, antibody formation.

RCT: Randomized controlled trial

Discussion

Despite the high prevalence of gout, there have been only a few randomized clinical trials on which conclusions can be based to aid the development of evidence-based medicine. Recommendations are often based on pathophysiological considerations. There is a clear need to fill in the gaps.

Some questions have not yet been researched conclusively, such as the effect of uric acid on the human body. For clinical practice it is of interest whether asymptomatic hyperuricemia is an independent cardiovascular risk factor or whether very low uric acid levels over long periods have an adverse effect on the central nervous system. Further research is also needed on the effect of uric acid on renal function. In summary, controlled trials on optimum uric acid level should be conducted, involving risk/benefit analysis of serum uric acid.

Further studies from which conclusions can be drawn researching the optimum time to begin treatment for chronic gout would also be of practical interest. Can uric acid-lowering therapy be started as early as during an acute gout flare? To date, only one, single-center study with a total of 57 patients has addressed this question (e22). This found no adverse effect on the frequency of gout flares as a result of beginning uric acid-lowering therapy early (less than 7 days after the beginning of a gout flare).

After a long hiatus in treatment options, there are now new options on the market. How useful they are remains to be the 1 last update 2020/07/07 seen.After a long hiatus in treatment options, there are now new options on the market. How useful they are remains to be seen.

A new drug for the treatment of acute gout is the IL-1 antagonist canakinumab. This is authorized for use when the 3 standard treatment options (NSAIDs, corticosteroids, and colchicine) are not tolerated, insufficiently effective, or contraindicated. Newly on the market for chronic gout is lesinurad, which is authorized for use in combination with a xanthine oxidase inhibitor for patients whose gout is refractory to standard treatment (a xanthine oxidase inhibitor or probenecid).

Conclusion for clinical practice

It is important to respond to gout appropriately at an early stage in order to avoid painful, chronic disease for patients. To improve compliance, particular emphasis should be placed on educating and involving patients. Regular laboratory testing should be performed during treatment to monitor progression. Withdrawal may be attempted after therapy has successfully lowered uric acid levels for several years.

​

eTable

Dosing of allopurinol for patients with kidney failure
Creatinine clearance
(mL/min)
Daily allopurinol dose
(mg)
100300
80250
60200
40150
20100
10100 every other day
0100 every 3 days
Hemodialysis
(2 to 3 times/week)
300 soon after each
dialysis session

According to Pazár Maldonado and So (e18)

Key Messages

  • Increased uric acid levels that are not causing a disease such as gout or urolithiasis are not an indication for pharmacotherapy (C).

  • Acute gout requires pharmacotherapy (nonsteroidal anti-inflammatory drugs, corticosteroids, or colchicine). Optimum results are achieved if pharmacotherapy is begun as soon as possible, preferably within 12 to 24 hours of onset of pain (B).

  • After a first gout flare the patient should be informed of possible lifestyle changes. Patient education should be provided to improve compliance (C).

  • Nonpharmacological treatment (raising and cooling the joint) can be recommended concomitantly (C).

  • The literature recommends beginning long-term treatment no sooner than 2 weeks after an acute gout flare if the following symptoms are present (B):

    • More than 2 gout flares per year

    • Urolithiasis and gout

    • Known overproduction of uric acid, e.g. during for 1 last update 2020/07/07 chemotherapyKnown overproduction of uric acid, e.g. during chemotherapy

    • Tophi

Acknowledgments

Translated from the original German by Caroline Shimakawa-Devitt, M.A.

Footnotes

Conflict of interest the 1 last update 2020/07/07 statementConflict of interest statement

The authors declare that no conflict of interest exists.

References

1. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2007;67:960–966. [PMC free article] [PubMed] [Google Scholar]
2. Kuo C, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat the 1 last update 2020/07/07 Rev Rheumatol. Nat Rev Rheumatol. 2015;11:649–662. [PubMed] [Google Scholar]
3. Cottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam the 1 last update 2020/07/07 Pract. BMC Fam Pract. 2013;14 [PMC free article] [PubMed] [Google Scholar]
4. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Engel B, Bleckwenn M, Weckbecker K. [How do family practitioners treat gout? Results of a survey in NRW] Z Allg Med. 2014;90:277–281. [Google Scholar]
5. Kiltz U, Alten R, Fleck M, et al. Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich) Rheumatol. 2016;75 [PubMed] [Google Scholar]
6. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann the 1 last update 2020/07/07 Rheum Dis. Ann Rheum Dis. 2017;76:29–42. [PubMed] [Google the 1 last update 2020/07/07 Scholar][Google Scholar]
7. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout Part I: Diagnosis. Report of a task force of the standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Ann Rheum Dis. 2006;65:1301–1311. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for [PMC free article] [PubMed] [Google Scholar]
8. Terkeltaub RA. Gout. N Engl J Med. 2003; the 1 last update 2020/07/07 349349:1647–1655. [PubMed] [Google Scholar]
9. Campion E, Delabry L. Asymptomatic hyperuricemia Risks and consequences in the normative aging study. Am the 1 last update 2020/07/07 J Med. Am J Med. 1987;82:421–426. [PubMed] [Google Scholar][Google Scholar]
10. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. the 1 last update 2020/07/07 Rheumatology (Oxford) Rheumatology (Oxford) 2010;49:1229–1238. [PubMed] [Google Scholar]
11. Taylor W, Fransen J, Jansen T, et al. Study for updated gout classification criteria (SUGAR): identification of features to classify gout. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Arthritis Care Res (Hoboken) 2015;67:1304–1315. [PMC free article] [PubMed] [Google Scholar]
12. Neogi T, Jansen T, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Arthritis Rheumatol. 2015;67:2557–2568. [PMC free article] [PubMed] [Google Scholar]
13. Tausche A, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U. Gout—current diagnosis and treatment. Dtsch Arztebl Int. 2009;hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for 106:549–555. [PMC free article] [PubMed] [Google Scholar]
14. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Ann Rheum Dis. 2006;65:1312–1324. [PMC free article] [PubMed] [Google Scholar]
15. Parathithasan N, Lee W, Pianta M, Oon S, Perera W. Gouty arthropathy: review of clinicopathologic and imaging features. J Med Imaging Radiat Oncol. 2016;60:9–20. [PubMed] [Google Scholar]Parathithasan N, Lee W, Pianta M, Oon S, Perera W. Gouty arthropathy: review of clinicopathologic and imaging features. J Med Imaging Radiat Oncol. 2016;60:9–20. [PubMed] [Google Scholar]
16. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Arthritis Care the 1 last update 2020/07/07 Res. 2012;64:1431–1446.Arthritis Care Res. 2012;64:1431–1446. [PMC free article] [PubMed] [Google Scholar]
17. Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for chronic gout. Cochrane Database Syst Rev. 2013; for 1 last update 2020/07/07 55 CD010039. [PMC free article] [PubMed] [Google Scholar]
18. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for acute gout. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Cochrane Database Syst Rev. 2013;11 CD010519. [PubMed] [Google Scholar]
19. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for van Durme CMPG, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RBM. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;9 CD010120. [PubMed] [Google Scholar]
20. Janssens HJEM, Janssen M, van de Lisdonk EH, van Riel PLCM, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Lancet. 2008;371:1854–1860. [PubMed] [Google Scholar]
21. Stack A, Hanley A, Casserly L. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. Q J Med. 2013;106:647–658. [PubMed] hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for [Google Scholar]
22. Terkeltaub RA. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first the 1 last update 2020/07/07 multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–1068. [PubMed] [Google Scholar]Terkeltaub RA. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–1068. [PubMed] [Google Scholar]
23. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;4 CD009920. [PubMed] [Google Scholar]
24. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Sivera F, Wechalekar MD, Andrés M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014;9 CD009993. [PubMed] [Google Scholar]
25. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447–1461. [PMC free article] [PubMed] [Google Scholar]
26. Vinik O, Wechalekar M, Falzon L, Buchbinder R, van der Heijde D, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a Systematic literature review. J Rheumatol. 2014; for 1 last for 1 last update 2020/07/07 update 2020/07/07 9292:70–74.J Rheumatol. 2014; for 1 last update 2020/07/07 9292:70–74. [PubMed] [Google Scholar]Vinik O, Wechalekar M, Falzon L, Buchbinder R, van der Heijde D, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a Systematic literature review. J Rheumatol. 2014; for 1 last for 1 last update 2020/07/07 update 2020/07/07 9292:70–74.J Rheumatol. 2014; for 1 last update 2020/07/07 9292:70–74. [PubMed] [Google Scholar]
27. Engel B, Prautzsch H. [Management of gout—new guidelines published by the German College of General Practitioners and Family Physicians (DEGAM)] Z Allg Med. 2014;90:7–12. [Google Scholar]
28. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla J. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006; the 1 last update 2020/07/07 5555:786–790. [PubMed] [Google Scholar]
29. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for N Engl J Med. 2005;353:2450–2461. [PubMed] [Google Scholar]
30. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429–2432. [PubMed] [Google Scholar]
31. Wortmann R, MacDonald P, Hunt B, Jackson R. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32:2386–2397.Clin Ther. 2010;32:2386–2397. [PubMed] [Google Scholar]
32. Schumacher R, Becker M, Wortmann R, et al. Effects of Febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis for 1 last update 2020/07/07 Rheum. 2008;59:1540–1548.Arthritis Rheum. 2008;59:1540–1548. [PubMed] [Google Scholar]
33. Seth R, Kydd ASR, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database the 1 last update 2020/07/07 Syst Rev. Cochrane Database Syst Rev. 2014;10 CD006077. [PubMed] hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for [Google Scholar]
34. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012;11 CD008653. [PMC free article] [PubMed] [Google Scholar]
35. Reinders M, Haagsma C, Jansen T. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892–897. [PubMed] [Google Scholar]
36. Fleischmann R, Kerr B, Yeh L, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricemia. Rheumatology (Oxford) 2014;53:2167–2174. [PubMed] [Google Scholar]
37. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study) Arthritis Rheumatol. 2017;69:203–212. [PubMed] [Google Scholar]
38. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41:925–935. [PubMed] hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for [Google for 1 last update 2020/07/07 Scholar][Google Scholar]
E1. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443–449. [PubMed] [Google Scholar]Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443–449. [PubMed] [Google Scholar]
E2. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Wise E, Khanna PP. The impact of gout guidelines. Curr Opin Rheumatol. 2015;27:225–230. [PubMed] [Google Scholar]
E3. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68:1265–1270. [PubMed] [Google Scholar]
E4. National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. Gout. www.cdc.gov/arthritis/basics/gout.htm (last accessed on 25 September 2016) [Google Scholar]
E5. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22:165–172. [PubMed] [Google Scholar]
E6. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Clev Clin J Med. 2002; the 1 last update 2020/07/07 6969 [PubMed] [Google Scholar]
E7. Janssens H, Fransen J, van de Lisdonk E, van Riel P, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170:1120–1126. [PubMed] [Google Scholar]Janssens H, Fransen J, van de Lisdonk E, van Riel P, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170:1120–1126. [PubMed] [Google Scholar]
E8. Jordan RW, Khan SA. The management of gout in primary care. InnovAiT. 2012;5:503–508. hand exercises for rheumatoid arthritis pdfhow to hand exercises for rheumatoid arthritis pdf for [Google Scholar]
E9. Reuss-Borst M. [Differential diagnosis and therapy of gout] Med Klin (Munich) 2009;104:710–720. [PubMed] [Google Scholar]Reuss-Borst M. [Differential diagnosis and therapy of gout] Med Klin (Munich) 2009;104:710–720. [PubMed] [Google Scholar]
E10. Dalbeth N, Doyle AJ. Imaging of gout—an overview. Best Pract Res Clin Rheumatol. 2012; for 1 last update 2020/07/07 2626:823–838. [PubMed] [Google Scholar]
E11. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013; the 1 last update 2020/07/07 7272:826–830. [PubMed]